Showing results (211-220 of 270) with videos related to
Sort By:
Pageof 27
JTO Clinical and Research Reports|April 27, 2026
Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARDByoung Chul Cho, Makoto Nishio, Myung-Ju Ahn, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARDSarah B Goldberg, Myung-Ju Ahn, Christina Baik, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2018
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLCXiuning Le, Sonam Puri, Marcelo V Negrao, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
Incorporating an NCCN-Based Systemic Therapy CNS Activity Score Into SRS Decision-Making for Patients With 5 or More Brain MetastasesThomas H Beckham, Stephanie O Dudzinski, Michael K Rooney, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief ReportHidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 24, 2025
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case ReportBingnan Zhang, Komal B Shah, Mitchell Parma, et al.Cell Reports. Medicine|November 9, 2023
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort BXiuning Le, Luis G Paz-Ares, Jan Van Meerbeeck, et al.Cancer Cell|February 14, 2023
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistanceMonique B Nilsson, Yan Yang, Simon Heeke, et al.Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
CT-Based Deep Foundation Model for Predicting Immune Checkpoint Inhibitor-Induced Pneumonitis Risk in Lung CancerAmgad Muneer, Eman Showkatian, Yuliya Kitsel, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2023
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLCKaiwen Wang, Robyn Du, Nathaniel J Myall, et al.Pageof 27